Table 1 Baseline characteristics of the study population
|  | Total study population (n = 772) | non-SDFR group (n = 623) | SDFR group (n = 149) |
|---|---|---|---|
Age (years), mean (SD) | 58.0 (15.4) | 56.6 (15.2) | 64.0 (14.9) |
Females, n (%) | 528 (68.4) | 435 (70.7) | 88 (59.1) |
ACPA positivity+ n (%) | 348 (45.1) | 333 (54.1) | 15 (10.1) |
Symptom duration at diagnosis+ (≤ 12 vs > 12 weeks), n (%) | 257 (33.5) | 207 (33.2) | 50 (33.6) |
DAS at baseline+, med (IQR) | 3.10 (2.52–3.72) | 3.10 (2.51–3.69) | 3.10 (2.55–3.91) |
SJC at baseline+, (0–44), med (IQR) | 6 (3–11) | 6 (3–11) | 8 (4–13) |
TJC at baseline+, (0–53), med (IQR) | 6 (4–9) | 6 (4–10) | 6 (4–9) |
ESR+ (mm/h), med (IQR) | 29 (14–45) | 29 (14–45) | 29 (14–47) |
VAS+ (0–100 mm), med (IQR) | 40 (20–60) | 41 (20–60) | 38 (20–60) |